Comparative Pharmacology
Head-to-head clinical analysis: EZALLOR SPRINKLE versus LANSOPRAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EZALLOR SPRINKLE versus LANSOPRAZOLE.
EZALLOR SPRINKLE vs LANSOPRAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EZALLOR SPRINKLE (rosuvastatin) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. It increases hepatic LDL receptor expression, enhancing LDL clearance from plasma and reducing VLDL synthesis.
Proton pump inhibitor that inhibits gastric acid secretion by binding to the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, preventing the final step of acid production.
40 mg orally once daily at bedtime; initial dose may be 20 mg. Dose range: 20-80 mg orally once daily.
15-30 mg orally once daily; 30 mg IV over 30 minutes once daily (when oral not possible).
None Documented
None Documented
Clinical Note
moderateDexlansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateLansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Lansoprazole."
Clinical Note
moderateDexlansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateTerminal elimination half-life is approximately 19 hours (range 13-20 hours) in healthy volunteers; half-life is prolonged in patients with hepatic impairment and severe renal impairment, necessitating dose adjustments.
Terminal elimination half-life: 1.5-2 hours (increased to 3-6 hours in elderly, hepatic impairment).
Renal excretion accounts for approximately 88% of the administered dose (56% as unchanged rosuvastatin and 32% as metabolites); fecal excretion accounts for approximately 12%.
Renal (14-23% as metabolites); biliary/fecal (major route, ~60% as metabolites and parent drug).
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor
Lansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole."